Nicolas Albin

1.5k total citations
34 papers, 662 citations indexed

About

Nicolas Albin is a scholar working on Oncology, Economics and Econometrics and Molecular Biology. According to data from OpenAlex, Nicolas Albin has authored 34 papers receiving a total of 662 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 12 papers in Economics and Econometrics and 9 papers in Molecular Biology. Recurrent topics in Nicolas Albin's work include Health Systems, Economic Evaluations, Quality of Life (12 papers), Pharmaceutical Economics and Policy (10 papers) and Economic and Financial Impacts of Cancer (6 papers). Nicolas Albin is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (12 papers), Pharmaceutical Economics and Policy (10 papers) and Economic and Financial Impacts of Cancer (6 papers). Nicolas Albin collaborates with scholars based in France, United States and Sweden. Nicolas Albin's co-authors include Lori Coward, Stephen Barnes, Marion Kirk, Martin R. Johnson, Robert B. Diasio, Orlando Parise, Alain Gouyette, Jackie Morizet, Guy G. Chabot and Marie‐Christine Mathieu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Annals of Oncology.

In The Last Decade

Nicolas Albin

31 papers receiving 641 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Nicolas Albin France 13 305 249 209 108 74 34 662
Kelly K. Filipski United States 12 505 1.7× 195 0.8× 299 1.4× 81 0.8× 106 1.4× 26 1.1k
Rosalynn Gill United States 13 235 0.8× 334 1.3× 128 0.6× 160 1.5× 26 0.4× 30 790
Susan E. Pratt United States 15 553 1.8× 425 1.7× 56 0.3× 69 0.6× 62 0.8× 26 986
Jin Shi China 14 207 0.7× 202 0.8× 160 0.8× 73 0.7× 28 0.4× 33 638
Thiravud Khuhaprema Thailand 18 289 0.9× 224 0.9× 80 0.4× 90 0.8× 36 0.5× 25 812
Christian Trautwein Germany 16 141 0.5× 204 0.8× 126 0.6× 60 0.6× 33 0.4× 31 800
Craig Eagle United States 13 536 1.8× 254 1.0× 240 1.1× 216 2.0× 89 1.2× 26 1.6k
Haw-Jyh Chiu United States 10 384 1.3× 268 1.1× 62 0.3× 40 0.4× 234 3.2× 16 894
Yon‐Dschun Ko Germany 19 277 0.9× 444 1.8× 50 0.2× 141 1.3× 116 1.6× 63 917
Milly E. de Jonge Netherlands 14 282 0.9× 219 0.9× 211 1.0× 29 0.3× 150 2.0× 17 867

Countries citing papers authored by Nicolas Albin

Since Specialization
Citations

This map shows the geographic impact of Nicolas Albin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Albin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Albin more than expected).

Fields of papers citing papers by Nicolas Albin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Albin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Albin. The network helps show where Nicolas Albin may publish in the future.

Co-authorship network of co-authors of Nicolas Albin

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Albin. A scholar is included among the top collaborators of Nicolas Albin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Albin. Nicolas Albin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Emmerich, Joseph, et al.. (2023). Prevention and management of health products shortages by the French national agency (ANSM), 10 years of experience. Frontiers in Public Health. 11. 1293110–1293110. 4 indexed citations
2.
Jacquet, Emmanuelle, et al.. (2023). Access to innovation through clinical trials and the national early access program for patients with lung cancer in France: focus on atezolizumab and durvalumab. Cancer Chemotherapy and Pharmacology. 92(3). 223–228. 2 indexed citations
3.
Jacquet, Emmanuelle, et al.. (2022). Survival, cost and added therapeutic benefit of drugs granted early access through the French temporary authorization for use program in solid tumors from 2009 to 2019. International Journal of Cancer. 151(8). 1345–1354. 8 indexed citations
4.
5.
Guillot, B., et al.. (2021). Access to innovation through the national early access program and clinical trials for patients with malignant melanoma. Cancer. 127(13). 2262–2270. 4 indexed citations
6.
Jacquet, Emmanuelle, et al.. (2021). Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years. European Journal of Cancer. 149. 82–90. 11 indexed citations
7.
Albin, Nicolas, et al.. (2018). Médecine de précision : une avancée majeure dans des situations spécifiques, un mythe dans les cancers réfractaires ?. Bulletin du Cancer. 105(4). 375–396. 6 indexed citations
8.
Albin, Nicolas, Jean‐François Bergmann, Olivier Blin, et al.. (2018). Early access to health products in France: Major advances of the French “Conseil stratégique des industries de santé” (CSIS) to be implemented (modalities, regulations, funding). Therapies. 74(1). 103–117. 6 indexed citations
9.
Mamzer, Marie‐France, Sophie Dubois, Nicolas Albin, et al.. (2017). How to strengthen the presence of patients in health technology assessments conducted by the health authorities. Therapies. 73(1). 95–105. 7 indexed citations
10.
Albin, Nicolas, et al.. (2017). How to assess a cancer therapy? Feedback from the French HTA body on the ESMO-MCBS. Annals of Oncology. 28. v642–v642. 2 indexed citations
11.
Mamzer, Marie‐France, Sophie Dubois, Nicolas Albin, et al.. (2017). Comment renforcer la place des patients dans les évaluations des technologies de santé faites par les autorités de santé. Therapies. 73(1). 83–93. 3 indexed citations
12.
Barkholt, Lisbeth, P Hentschke, Henrik Zetterquist, et al.. (2001). An allogeneic anti-cancer effect after hematopoietic stem cell transplantation. Transplantation Proceedings. 33(1-2). 1862–1864.
13.
Lokiec, François, Frédéric Pinguet, Stéphane Culine, et al.. (2000). Population pharmacokinetics of topotecan: intraindividual variability in total drug. Cancer Chemotherapy and Pharmacology. 46(5). 375–381. 30 indexed citations
14.
Soussain, Carole, Bertrand Souleau, Jean Gabarre, et al.. (1999). Intensive Chemotherapy with Hematopoietic Cell Transplantation after ESHAP Therapy for Relapsed or Refractory Non-Hodgkin's Lymphoma. Results of a Single-Centre Study of 65 Patients. Leukemia & lymphoma. 33(5-6). 543–550. 27 indexed citations
15.
Johnson, Martin R., et al.. (1997). Semi-automated radioassay for determination of dihydropyrimidine dehydrogenase (DPD) activity screening cancer patients for DPD deficiency, a condition associated with 5-fluorouracil toxicity. Journal of Chromatography B Biomedical Sciences and Applications. 696(2). 183–191. 79 indexed citations
16.
Coward, Lori, Marion Kirk, Nicolas Albin, & Stephen Barnes. (1996). Analysis of plasma isoflavones by reversed-phase HPLC-multiple reaction ion monitoring-mass spectrometry. Clinica Chimica Acta. 247(1-2). 121–142. 162 indexed citations
17.
Albin, Nicolas, Martin R. Johnson, & Robert B. Diasio. (1996). cDNA cloning of bovine liver dihydropyrimidine dehydrogenase. DNA sequence. 6(4). 243–250. 12 indexed citations
18.
Nehmé, A, Nicolas Albin, Sylvie M. Guichard, et al.. (1995). Mechanism of interaction between cisplatin and human recombinant interferon gamma in human ovarian‐cancer cell lines. International Journal of Cancer. 61(5). 643–648. 12 indexed citations
19.
Parise, Orlando, François Janot, B Luboïnski, et al.. (1994). Thymidylate synthase activity, folates, and glutathione system in head and neck carcinoma and adjacent tissues. Head & Neck. 16(2). 158–164. 13 indexed citations
20.
Albin, Nicolas, Marie‐Christine Mathieu, Jackie Morizet, et al.. (1993). Main drug-metabolizing enzyme systems in human breast tumors and peritumoral tissues.. PubMed. 53(15). 3541–6. 95 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kelly K. Filipski Breakdown of academic impact, for papers by Rosalynn Gill Breakdown of academic impact, for papers by Susan E. Pratt Breakdown of academic impact, for papers by Jin Shi Breakdown of academic impact, for papers by Thiravud Khuhaprema Breakdown of academic impact, for papers by Christian Trautwein Breakdown of academic impact, for papers by Craig Eagle Breakdown of academic impact, for papers by Haw-Jyh Chiu Breakdown of academic impact, for papers by Yon‐Dschun Ko Breakdown of academic impact, for papers by Milly E. de Jonge
Rankless by CCL
2026